1 ml of Ospolot oral suspension contains 20 mg of sultiam. It is intended for the treatment of SeLECTS (Self-Limited Epilepsy with Centrotemporal Spikes) (formerly Rolandic epilepsy) in children and adolescents aged 3 years and older who do not respond to or are intolerant of other treatments, or for whom there are no other therapeutic alternatives.
Ospolot 250 ml oral suspension comes in a glass bottle with a child-resistant cap. It is supplied in a cardboard box containing a 10 ml oral syringe with a 0.25 ml scale and an adapter for the oral syringe.
Ospolot oral suspension is a prescription-only medicine and is distributed by TwinPharma BV. Desitin Arzneimittel GmbH is the marketing authorisation holder.